Skip to main navigation Skip to search Skip to main content

A phase 2 study of inotuzumab ozogamicin in children and young adults with relapsed or refractory CD22+B-acute lymphoblastic leukemia (B-ALL), CO ID AALL1621/Pfizer no W1221468

Upstate Medical University

Project: Research

Project Details

StatusActive
Effective start/end date04/1/22 → 03/31/27

Funding

  • Public Health Institute: $1,500.00